Thu, 11 June 2015
Research released at the 2015 American Society of Clinical Oncology (ASCO) annual meeting showed great promise for squamous cell lung cancer patients taking the immunotherapy drug Opdivo (nivolumab). But can we predict which patients will do well on it?
Direct download: GRACEcast-332_ASCO_2015_Immunotherapy_Opdivo_Squamous_NSCLC.mp4
Category:Lung-Cancer-Video -- posted at: 4:39pm PDT